Immatics NV
IMTX6.501USD
+0.021+0.33%
交易中 （美東）報價延遲15分鐘
790.21M總市值
虧損本益比TTM
關於 Immatics NV 公司
Immatics NV 是一家位於荷蘭的臨牀階段生物製藥公司。該公司專注於發現和開發 T 細胞受體，旨在實現針對這些靶標的強大而特異性的 T 細胞反應。該公司開發靶向免疫療法，重點是通過兩種不同的治療方式治療實體腫瘤：過繼細胞療法 (ACT) 和抗體樣 TCR 雙特異性 (TCER)。其全資擁有的管線包括八個治療項目，其中四個處於臨牀試驗階段，包括用於實體癌的IMA201（MAGEA4/8）、IMA202（MAGEA1）和ACTolog IMA 101（多目標試點試驗）以及用於血液病和實體癌的IMA203（PRAME）；還有四個處於臨牀前開發階段，包括用於實體癌的IMA204（COL6A3）和IMA401（癌症睾丸抗原），以及用於血液病和實體癌的ACTallo IMA301（癌症睾丸抗原）和IMA402（癌症睾丸抗原）。
公司簡介
公司代碼IMTX
公司名稱Immatics NV
上市日期Jul 02, 2020
CEODr. Harpreet Singh, Ph.D.
員工數量297
證券類型Ordinary Share
年結日Jul 02
公司地址Paul Ehrlich-Strasse 15
城市TUEBINGEN
上市交易所NASDAQ Capital Market Consolidated
國家Germany
郵編72076
電話4970715397700
網址https://immatics.com/
公司代碼IMTX
上市日期Jul 02, 2020
CEODr. Harpreet Singh, Ph.D.
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Mr. Peter Chambre
Mr. Peter Chambre
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
405.15K
+8.54%
Dr. Steffen Walter, Ph.D.
Dr. Steffen Walter, Ph.D.
Chief Operating Officer
Chief Operating Officer
380.70K
+36.02%
Dr. Mathias Hothum, Ph.D.
Dr. Mathias Hothum, Ph.D.
Non-Executive Director
Non-Executive Director
354.52K
+7.59%
Mr. Jordan Silverstein
Mr. Jordan Silverstein
Head of Strategy
Head of Strategy
282.48K
+44.00%
Mr. Arnd Christ
Mr. Arnd Christ
Chief Financial Officer
Chief Financial Officer
276.84K
+62.94%
Mr. Edward Sturchio
Mr. Edward Sturchio
General Counsel
General Counsel
200.00K
+87.14%
Mr. Paul Rutherford Carter
Mr. Paul Rutherford Carter
Non-Executive Independent Director
Non-Executive Independent Director
87.19K
+57.63%
Mr. Michael G. (Mike) Atieh
Mr. Michael G. (Mike) Atieh
Non-Executive Independent Director
Non-Executive Independent Director
87.19K
+57.63%
Dr. Alise S. Reicin, M.D.
Dr. Alise S. Reicin, M.D.
Temporary Non-Executive Director
Temporary Non-Executive Director
10.00K
--
Mr. Adam Stone
Mr. Adam Stone
Non-Executive Independent Director
Non-Executive Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Peter Chambre
Mr. Peter Chambre
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
405.15K
+8.54%
Dr. Steffen Walter, Ph.D.
Dr. Steffen Walter, Ph.D.
Chief Operating Officer
Chief Operating Officer
380.70K
+36.02%
Dr. Mathias Hothum, Ph.D.
Dr. Mathias Hothum, Ph.D.
Non-Executive Director
Non-Executive Director
354.52K
+7.59%
Mr. Jordan Silverstein
Mr. Jordan Silverstein
Head of Strategy
Head of Strategy
282.48K
+44.00%
Mr. Arnd Christ
Mr. Arnd Christ
Chief Financial Officer
Chief Financial Officer
276.84K
+62.94%
Mr. Edward Sturchio
Mr. Edward Sturchio
General Counsel
General Counsel
200.00K
+87.14%
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 5月17日 週六
更新時間: 5月17日 週六
持股股東
股東類型
持股股東
持股股東
佔比
DH Capital GmbH & Co. KG
14.15%
T. Rowe Price Investment Management, Inc.
12.07%
Perceptive Advisors LLC
7.72%
Suvretta Capital Management, LLC
7.52%
Wellington Management Company, LLP
7.06%
Other
51.48%
持股股東
持股股東
佔比
DH Capital GmbH & Co. KG
14.15%
T. Rowe Price Investment Management, Inc.
12.07%
Perceptive Advisors LLC
7.72%
Suvretta Capital Management, LLC
7.52%
Wellington Management Company, LLP
7.06%
Other
51.48%
股東類型
持股股東
佔比
Investment Advisor/Hedge Fund
22.62%
Hedge Fund
19.28%
Corporation
18.19%
Investment Advisor
16.37%
Private Equity
11.31%
Research Firm
5.99%
Individual Investor
4.66%
Venture Capital
2.82%
Endowment Fund
0.57%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
213
123.88M
101.92%
-15.72M
2025Q1
214
124.44M
102.37%
-14.20M
2024Q4
208
124.50M
104.31%
+7.71M
2024Q3
202
107.38M
100.53%
-7.52M
2024Q2
201
107.32M
100.55%
-1.74M
2024Q1
188
101.29M
94.78%
+19.35M
2023Q4
166
76.94M
93.30%
+2.21M
2023Q3
155
70.38M
86.16%
+3.44M
2023Q2
153
67.89M
85.91%
+7.49M
2023Q1
143
61.60M
80.34%
+3.04M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
DH Capital GmbH & Co. KG
17.20M
14.15%
--
--
Jan 31, 2025
T. Rowe Price Investment Management, Inc.
14.68M
12.07%
+524.45K
+3.71%
Mar 31, 2025
Perceptive Advisors LLC
9.38M
7.72%
--
--
Mar 31, 2025
Suvretta Capital Management, LLC
9.14M
7.52%
+1.25M
+15.90%
Mar 31, 2025
Wellington Management Company, LLP
8.58M
7.06%
-1.83M
-17.61%
Mar 31, 2025
Baker Bros. Advisors LP
7.28M
5.99%
--
--
Mar 31, 2025
Vestal Point Capital, LP
7.19M
5.92%
+917.70K
+14.62%
Mar 31, 2025
RTW Investments L.P.
6.91M
5.68%
+368.97K
+5.64%
Mar 31, 2025
AT Impf GmbH
4.91M
4.04%
--
--
Jan 22, 2024
The Vanguard Group, Inc.
3.75M
3.08%
--
--
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
Virtus LifeSci Biotech Clinical Trials ETF
0.79%
ALPS Medical Breakthroughs ETF
0.44%
SPDR S&P International Small Cap ETF
0.02%
Fidelity Nasdaq Composite Index ETF
0%
Goldman Sachs Innovate Equity ETF
0%
First Trust IPOX Europe Equity Opportunities ETF
0%
SPDR Portfolio Developed World ex-US ETF
0%
iShares Health Innovation Active ETF
0%
SPDR SSGA US Small Cap Low Volatility Index ETF
0%
SPDR S&P Kensho New Economies Composite ETF
0%
Virtus LifeSci Biotech Clinical Trials ETF
佔比0.79%
ALPS Medical Breakthroughs ETF
佔比0.44%
SPDR S&P International Small Cap ETF
佔比0.02%
Fidelity Nasdaq Composite Index ETF
佔比0%
Goldman Sachs Innovate Equity ETF
佔比0%
First Trust IPOX Europe Equity Opportunities ETF
佔比0%
SPDR Portfolio Developed World ex-US ETF
佔比0%
iShares Health Innovation Active ETF
佔比0%
SPDR SSGA US Small Cap Low Volatility Index ETF
佔比0%
SPDR S&P Kensho New Economies Composite ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
